Temporal mapping of the anti-tumor effects of nanobody-based MSLN.CAR-T cell therapy in metastatic solid tumors [total RNA-Seq]
RNA-seq (gene expression) · mouse · 34 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 34 samples: 7 conditions, mostly with about 5 replicates eachGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE303385_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1294984 and SRA study SRP602794. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 34 samples.
How we read this: 7 replicated groups read from 34 sample titles; they account for 34 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9124963 Untreated_Day0_1 Untreated_Day0
- GSM9124964 Untreated_Day0_2 Untreated_Day0
- GSM9124965 Untreated_Day0_3 Untreated_Day0
- GSM9124966 Untreated_Day0_4 Untreated_Day0
- GSM9124967 Untreated_Day0_5 Untreated_Day0
- GSM9124968 CART_Day2_1 CART_Day2
- GSM9124969 CART_Day2_2 CART_Day2
- GSM9124970 CART_Day2_3 CART_Day2
- GSM9124971 CART_Day2_4 CART_Day2
- GSM9124972 CART_Day7_1 CART_Day7
- GSM9124973 CART_Day7_2 CART_Day7
- GSM9124974 CART_Day7_3 CART_Day7
- GSM9124975 CART_Day7_4 CART_Day7
- GSM9124976 CART_Day7_5 CART_Day7
- GSM9124977 CART_Day12_1 CART_Day12
- GSM9124978 CART_Day12_2 CART_Day12
- GSM9124979 CART_Day12_3 CART_Day12
- GSM9124980 CART_Day12_4 CART_Day12
- GSM9124981 CART_Day12_5 CART_Day12
- GSM9124982 MockT_Day2_1 MockT_Day2
- GSM9124983 MockT_Day2_2 MockT_Day2
- GSM9124984 MockT_Day2_3 MockT_Day2
- GSM9124985 MockT_Day2_4 MockT_Day2
- GSM9124986 MockT_Day2_5 MockT_Day2
- GSM9124987 MockT_Day7_1 MockT_Day7
- GSM9124988 MockT_Day7_2 MockT_Day7
- GSM9124989 MockT_Day7_3 MockT_Day7
- GSM9124990 MockT_Day7_4 MockT_Day7
- GSM9124991 MockT_Day7_5 MockT_Day7
- GSM9124992 MockT_Day12_1 MockT_Day12
- GSM9124993 MockT_Day12_2 MockT_Day12
- GSM9124994 MockT_Day12_3 MockT_Day12
- GSM9124995 MockT_Day12_4 MockT_Day12
- GSM9124996 MockT_Day12_5 MockT_Day12
- GSE303224 Temporal mapping of the anti-tumor effects of nanobody-based MSLN.CAR-T cell therapy in metastatic solid tumors [scRNA-Seq] 32 samples shares car-t, msln, nanobody-based, anti-tumor, metastatic, temporal, mapping, therapy
- GSE266166 B-ALL GPR65 expression influences susceptibility to CAR-T therapy through a VEGF and macrophage-dependent mechanism 22 samples shares car-t, therapy
- GSE287413 CAR-T cell therapy for chronic kidney disease 12 samples shares car-t, therapy
- GSE326798 CDK4/6 Inhibition Enhances CAR-T Cell Therapy in Solid Tumors 12 samples shares car-t, therapy
- GSE234977 Pan-cancer mapping of single CD8+ T cell profiles reveals a TCF1:CXCR6 axis regulating CD28 co-stimulation and anti-tumor immunity 32 samples shares anti-tumor, mapping
- GSE234974 Pan-cancer mapping of single CD8+ T cell profiles reveals a TCF1:CXCR6 axis regulating CD28 co-stimulation and anti-tumor immunity I 24 samples shares anti-tumor, mapping
- GSE294347 Rationalistic Modulation of Immune Mechanisms Synergizes the Anti-Tumor Effects of Targeted Radiation Therapy in Pre-clinical Models 14 samples shares anti-tumor, therapy
- GSE231357 Syndecan-1 inhibition promotes anti-tumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy 14 samples shares anti-tumor, therapy
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.